6/25/2025 Categories: Industries Angelini Industries: in 2024 net income up 30% to € 156 million. Group revenues (+3%) and EBITDA (+17%) also on the rise
6/16/2020 Categories: Industries Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
Angelini Industries
